Associations between legal performance-enhancing substance use and future cardiovascular disease risk factors in young adults: A prospective cohort study

Jason M. Nagata¹ *, Kyle T. Ganson², Mitchell L. Cunningham³, Deborah Mitchison⁴,⁵, Jason M. Lavender⁶,⁷, Aaron J. Blashill⁸,⁹,¹⁰, Holly C. Gooding¹¹, Stuart B. Murray¹²

¹ Department of Pediatrics, University of California, San Francisco, San Francisco, California, United States of America, ² Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada, ³ School of Psychology, University of Sydney, Sydney, New South Wales, Australia, ⁴ Translational Health Research Institute, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia, ⁵ Department of Psychology, Macquarie University, Sydney, New South Wales, Australia, ⁶ Military Cardiovascular Outcomes Research Program (MiCOR), Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America, ⁷ The Metis Foundation, San Antonio, Texas, United States of America, ⁸ Department of Psychology, San Diego State University, San Diego, California, United States of America, ⁹ San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University, San Diego, California, United States of America, ¹⁰ San Diego Joint Doctoral Program in Clinical Psychology, University of California, San Diego, California, United States of America, ¹¹ Department of Psychiatry & Behavioral Sciences, University of Southern California, Los Angeles, California, United States of America

* jasonmnagata@gmail.com

Abstract

Background

Legal performance-enhancing substances (PES), such as creatine, are commonly used by adolescents and young adults. As PES are mostly unregulated by the US Food and Drug Administration, there has been limited empirical attention devoted to examining their long-term safety and health outcomes. Preliminary studies have demonstrated associations between PES use and severe medical events, including hospitalizations and death. PES could be linked to cardiovascular disease (CVD), the most common cause of mortality in the US, by altering the myocardium, vasculature, or metabolism. The objective of this study was to examine prospective associations between the use of legal PES in young adulthood and CVD risk factors at seven-year follow-up.

Materials and methods

Nationally representative longitudinal cohort data from the National Longitudinal Study of Adolescent to Adult Health, Waves III (2001–2002) and IV (2008), were analyzed. Regression models determined the prospective association between the use of legal PES (e.g. creatine monohydrate) and CVD risk factors (e.g. body mass index, diabetes, hypertension, hyperlipidemia), adjusting for relevant covariates.
Among the diverse sample of 11,996 male and female participants, no significant differences by PES use in body mass index, diabetes, hypertension, or hyperlipidemia were noted at Wave III. In unadjusted comparisons, legal PES users (versus non-users) were more likely to be White, be male, be college educated, drink alcohol, and engage in weightlifting, exercise, individual sports, team sports, and other strength training. There were no significant prospective associations between legal PES use at Wave III and body mass index, hemoglobin A1c, systolic and diastolic blood pressure, and cholesterol (total, HDL, LDL, triglycerides) deciles at seven-year follow-up (Wave IV), adjusting for demographics, health behaviors, and Wave III CVD risk factors. Similarly, there were no significant prospective associations between legal PES use and diabetes, hypertension, or hyperlipidemia based on objective measures or self-reported medications and diagnoses, adjusting for demographics, health behaviors, and Wave III CVD risk.

Conclusions
We do not find evidence for a prospective association between legal PES use and CVD risk factors in young adults over seven years of follow-up, including BMI, diabetes, hypertension, or hyperlipidemia. It should be noted that legal PES use was operationalized dichotomously and as one broad category, which did not account for frequency, amount, or duration of use. Given the lack of regulation and clinical trials data, observational studies can provide much needed data to inform the safety and long-term health associations of legal PES use and, in turn, inform clinical guidance and policy.

Introduction
Performance-enhancing substances (PES) are commonly used among adolescents and young adults and are associated with increased health risks [1, 2]. In the United States (US), PES can be delineated by legal status, where legal PES include substances such as creatine monohydrate and amino acids and illegal PES include anabolic-androgenic steroids (AAS) not prescribed for medical purposes. Research on AAS misuse has documented adverse social, psychological [3–6], and physiological [7–9] health outcomes, although AAS are less commonly used (3–6% among boys and men) compared to legal PES [1, 2]. In contrast, between 16–35% of adolescent and young adult males in the US have used legal PES in the past year [1, 2], with easy accessibility and lack of regulatory oversight of legal PES likely contributing to high use rates. Legal PES use has also been found to be prospectively associated with AAS misuse [10]. Notably, a recent study in young people documented that legal PES use, including muscle-enhancing or energy supplements, was associated with an increased risk of severe medical events (e.g., emergency room visits, disability, or premature death) when compared to vitamin use [11]. Unfortunately, there has been a dearth of research investigating health-related outcomes associated with legal PES use over the long term [3].

Cardiovascular health outcomes represent an area in particular need of investigation, given that many cardiovascular disease (CVD) risk factors (e.g., diabetes, hypertension, dyslipidemia) commonly develop in young adulthood when legal PES use is prevalent, and CVD remains the leading cause of death in the US [12, 13]. Legal PES may have effects on the
cardiovascular system by directly altering the myocardium, vasculature, or metabolism [14]. Furthermore, there is the potential for indirect effects by enabling users to push beyond normal physiologic limits with potential consequences of exercise-induced arrhythmias [14]. PES use is associated with eating disorders and muscle dysmorphia [15–17], which have cardiovascular consequences [18, 19]. These potential cardiovascular effects warrant further examination, especially given mixed findings in various short-term health-related outcomes. For example, short-term creatine supplementation is generally safe in adults [20], does not appear to adversely affect blood lipid profiles (e.g., cholesterol, triglycerides) [21], and may even have favorable glycemic effects (when combined with exercise) for individuals with type-2 diabetes [22]. However, creatine use also has been linked to weight gain [23], which could represent a detriment to long-term cardiovascular health, as higher weight and BMI are primary risk factors for CVD [24]. Additionally, recent reviews have found that stimulants are associated with significant elevations in systolic and diastolic blood pressure [25, 26]. Caffeine, a stimulant that can be used for performance enhancement and is commonly included in mixtures of legal PES, activates the sympathetic nervous system and catecholamines, leading to elevations in blood pressure [27, 28]. Finally, other legal forms of PES, such as androgen prohormones, could have particularly deleterious health-related impacts, especially if associated with adverse cardiovascular effects similar to those resulting from misuse of AAS (which they are designed to chemically emulate) [20].

Importantly, legal PES are often mislabeled and inaccurate in terms of their contents [11, 29, 30], which may explain serious medical outcomes that can be associated with their use. Specifically, there are concerns that a significant number of dietary supplementary products can be adulterated with potent stimulants (e.g., derivatives of methamphetamine) and other illicit substances (e.g., AAS) [31–34] with serious cardiovascular effects [14]. For instance, 15–60% of nutritional supplements were found to contain AAS when tested [35, 36]. A recent review found a link between AAS and CVD risk factors, including hypertension or dyslipidemia, in seven of the nine studies reviewed [37], consistent with prior reviews [38–41]. Potential mechanisms underlying this link include increased systemic inflammation, oxidative stress, and vascular dysfunction [41]. Consequently, it is plausible that use of a legal PES may promote CVD risk by virtue of the unlabeled ingredients or contaminants they may contain. Furthermore, amount, frequency, and duration of use are likely to be factors related to adverse outcomes. For example, high doses and prolonged use of AAS have been found to be associated with greater degrees of dyslipidemia [41].

In sum, although preliminary research points to a prospective link between legal PES use and severe medical complications, there is a need to investigate long-term, prospective associations with specific health outcomes. In the present study, we focus on CVD risk factors—including diabetes, hypertension, abnormal lipid profiles, and obesity—in young adulthood given that these outcomes may take many years to fully manifest [38, 42] and evidence suggesting that use of illegal PES (e.g., AAS) is associated with CVD risk factors [37–41]. Additionally, previous studies have been limited by small and/or highly specific samples (e.g., athletes) or comparison groups (e.g., vitamin users), warranting further evidence that large sample, population-based cohort studies are needed. Thus, the objective of this investigation was to examine the prospective association between legal PES use in young adulthood and several key CVD risk factors, using data collected in a nationally representative longitudinal cohort study.

**Materials and methods**

**Study population.** This study utilizes data from the National Longitudinal Study of Adolescent to Adult Health (Add Health). Add Health is a nationally representative longitudinal
cohort study which sampled adolescents throughout the United States and followed them into adulthood [43]. The baseline sample data was collected from 1994 to 1995 when participants were 11–18 years old by using systematic sampling methods and implicit stratification so that the selected high schools (n = 80) and paired middle schools were representative of US schools with respect to geographical region of the country, size, urbanicity, type (i.e. public, private, charter), and race/ethnicity. For this specific study, we used the nationally representative, restricted-use samples from Wave III (18–26 years, 2001–2002) and Wave IV (24–32 years, 2008). At Waves III and IV, data were collected via interview, lasting approximately 90 minutes, at the participant’s home or other suitable location. Immediately following the interview, interviewers took physical measurements and collected biological specimens. The University of North Carolina Institutional Review Board approved all Add Health study procedures and written informed consent was obtained. Further details about the study design can be found elsewhere [43].

**Measures.**

**Predictor.** The primary predictor variable of this study (asked at Wave III) was based on the question: “In the past year, have you used a legal performance enhancing substance for athletes (such as creatine monohydrate or andro)?” Response choices included “yes” or “no.”

**Outcomes.** The primary outcome measures of this study are listed below and included measurements of several CVD risk factors, such as body mass index (BMI), hemoglobin A1c, blood pressure, and cholesterol at Wave IV.

- **Body mass index (BMI).** was calculated using the standard formula weight (kilograms) divided by height (meters) squared (BMI = weight/height$^2$). Weight (Health-o-meter 844KL High Capacity Digital Bathroom Scale; Jarden Corporation; Rye, NY) and height (Carpenter’s square, steel tape measure) were measured by the interviewer. Change in BMI was calculated as Wave IV BMI minus Wave III BMI (e.g., positive values indicate BMI gain).

- **Hemoglobin A1c.** We examined hemoglobin A1c in Wave IV as a continuous outcome. Respondents in the study were also classified as having diabetes in Wave IV if they had levels of fasting glucose $\geq$ 126 mg/dl, non-fasting glucose $\geq$ 200 mg/dl, and hemoglobin A1c $\geq$ 6.5% [44], had a self-reported history of diabetes (except during pregnancy), or if they used anti-diabetic medication in the four weeks preceding the Wave IV assessment. We included self-reported diagnosis of diabetes at Wave III as a covariate.

- **Blood pressure.** We examined systolic and diastolic blood pressure as continuous outcomes, using the mean of two measurements separated by a 30 second interval from a factory-calibrated, Microlife BP3MC1-PC-IB oscillometric blood pressure monitor (Microlife USA, Inc.; Dunedin, FL). Hypertension was defined as a measured systolic blood pressure $\geq$130 mmHg or a measured diastolic blood pressure $\geq$80 mmHg [45], the use of anti-hypertensive medication in the four weeks preceding the Wave IV assessment, or an affirmative response to the query: “Have you ever been diagnosed with high blood pressure or hypertension?” In 2017, the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines lowered the threshold for systolic and diastolic blood pressure to define hypertension (130/80 from 140/90), expanding the number of young adults with hypertension [45]. This choice was based on meta-analyses of observational studies that demonstrated that elevated blood pressure and hypertension are associated with increased risk of CVD, end stage renal disease, subclinical atherosclerosis, and all-cause death [45]. We included self-reported diagnosis of high blood pressure or hypertension at Wave III as a covariate.

- **Cholesterol.** Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride deciles were defined as continuous outcomes for this study. Hyperlipidemia was defined as the total cholesterol decile corresponding to the proportion of young adults with a total cholesterol $\geq$240 mg/dL in the nationally representative
National Health and Nutrition Examination Surveys [12, 46], the use of antihyperlipidemic medication in the four weeks preceding the Wave IV assessment, or an affirmative response to the question: “Have you ever been diagnosed with high cholesterol, triglycerides, or lipids?” We included self-reported diagnosis of high cholesterol, triglycerides, or lipids at Wave III as a covariate.

**Additional covariates.** Included self-reported demographics such as age, sex, race/ethnicity, highest education (high school or less versus college or more), and household income, as these have been shown to be associated with both legal PES use [47] and CVD risk [48]. We evaluated household income as a covariate with data from parents’ self-report of household income in the last calendar year. Gaussian normal regression imputation models were used to impute the income for the 1,638 parents who did not respond, were uncomfortable answering the income question, or stated that they did not know, similar to the method used in previous studies [2]. Behavioral covariates that are associated with legal PES use and CVD risk [12, 47, 49] were assessed at Wave III, including self-reported alcohol use (≥2 days in the past month, yes/no), smoking (past 30 days, yes/no), AAS use (between Wave I and III, yes/no), and physical activity and sports context, including weight lifting to bulk up in the past 7 days (yes/no), exercising to bulk up in the past 7 days (yes/no), the number of times participating in individual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or martial arts) in the past 7 days (0–7), the number of times participating in strenuous team sports (football, soccer, basketball, lacrosse, rugby, field hockey, ice hockey) in the past 7 days (0–7), and the number of times participating in gymnastics, weight lifting, or strength training in the past 7 days (0–7).

**Statistical analysis**

Data analysis was performed using Add Health’s pre-constructed sample weights to provide a sample that was nationally representative [50]. Comparisons of descriptive characteristics between legal PES users versus non-users of legal PES were calculated using Pearson’s Chi-square tests for categorical variables and independent sample t-tests for continuous variables. Multiple linear regression models were used to evaluate the association between legal PES use (Wave III) and continuous CVD risk factors, including BMI, BMI change, hemoglobin A1c, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride deciles (Wave IV). Multiple logistic regressions were used to evaluate the association between legal PES use (Wave III) and subsequent dichotomous clinical CVD risk factors, including diabetes, hypertension, hyperlipidemia, and obesity (Wave IV). For each outcome, we present three regression models: 1) unadjusted, 2) adjusted for demographics and baseline CVD risk (adjusted for age, sex, race/ethnicity, BMI, and self-reported hypertension, hyperlipidemia, or diabetes at Wave III), and 3) fully adjusted (adjusted for age, sex, race/ethnicity, household income, highest education, smoking, alcohol, AAS, weightlifting, exercise, strength training, individual sports, team sports, BMI, and self-reported hypertension, hyperlipidemia, or diabetes at Wave III). Wave III and Wave IV measures of smoking, alcohol, strength training, individual sports, and team sports were included in the fully adjusted model. Analyses were conducted using Stata 15.1 (StataCorp, College Station, TX).

**Power calculations.** Given a sample size of legal PES users (n = 963) and non-users (n = 11,033), and using an estimated mean for i) BMI change (Wave III to IV): 2.5±4.3 kg/m², and ii) BMI (Wave IV): 29.0±7.5 kg/m², our study had statistical power (alpha = .05, two-sided) of >80% to detect a i) 0.4 kg/m² group difference in BMI change and ii) 0.7 kg/m² group difference in BMI at Wave IV. Using an estimated mean for i) hemoglobin A1c 5.59 ±0.80%, ii) systolic blood pressure of 125.02±13.69 mmHg, iii) diastolic blood pressure of
79.37±10.21 mmHg, and iv) cholesterol deciles of 5.44±2.88, our study had statistical power (alpha = .05, two-sided) of >80% to detect i) 0.08% group difference in hemoglobin A1c, ii) 1.28 mmHg group difference in systolic blood pressure, iii) 0.96 mmHg group difference in diastolic blood pressure, and iv) 0.27 group difference in cholesterol deciles. Given a sample size of legal PES users (n = 963) and non-users (n = 11,033), and using an estimated i) 6.5% with diabetes, ii) 51.9% with hypertension, and iii) 16.6% with hyperlipidemia, our study had statistical power (alpha = .05, two-sided) of >80% to detect odds ratios of i) 1.21 for hypertension, ii) 1.28 for hyperlipidemia, and iii) 1.41 for diabetes, respectively.

**Results**

Overall, the 11,996 participants included in the analysis were on average 22 years of age at Wave III and were racially and ethnically diverse. Comparisons of descriptive and health characteristics of the sample are presented in Table 1, organized by legal PES use versus no use. In unadjusted comparisons, legal PES users were more likely to be White, male, college-educated, drink alcohol, and engage in weightlifting, exercise, individual sports, team sports, and other strength training than non-users. Legal PES users had higher parental household income than non-users. Frequency of health behaviors such as alcohol, smoking, and physical activity remained relatively stable over seven-year follow-up, except for the number of times participating in team sports, which decreased over follow-up. There were no significant differences in BMI or self-reported diabetes, hypertension, or hyperlipidemia diagnoses between PES users and non-users at Wave III. During the seven-year follow-up period, prevalence of diabetes, hypertension, and hyperlipidemia increased.

Table 2 presents linear regression models with legal PES use as the independent variable and continuous CVD risk factors at seven-year follow-up as the dependent variable. In unadjusted linear regression models, legal PES use was associated with higher systolic blood pressure, a lower HDL cholesterol decile, and a higher triglyceride decile. In models adjusting for demographics, health behaviors, and Wave III CVD risk, there were no significant prospective associations between legal PES use and BMI, hemoglobin A1c, systolic blood pressure, and cholesterol (total, HDL, LDL, triglycerides) deciles at seven-year follow-up except for diastolic blood pressure. Legal PES use was associated with lower diastolic blood pressure in partially adjusted models, but the association was attenuated and was no longer statistically significant after adjusting for behavioral covariates. Table 3 presents logistic regression models with legal PES use as the independent variable and dichotomous CVD risk factors at seven-year follow-up as the dependent variable. There were no significant prospective associations between legal PES use and diabetes, hyperlipidemia, or obesity based on objective measures or self-reported medications and diagnoses, adjusting for demographics, health behaviors, and Wave III CVD risk at seven-year follow-up. Legal PES use was associated with lower odds of hypertension in partially adjusted models, but the association was attenuated and was no longer statistically significant after adjusting for behavioral covariates.

**Discussion**

In this nationally representative cohort study of nearly 12,000 young adults in the US, we did not find significant prospective associations between legal PES use and CVD risk factors, including blood pressure, diabetes, lipids, and BMI, when adjusting for theoretically relevant covariates. Legal PES use was more common among males and participants with White race, higher education, higher income, alcohol use, and engagement in weightlifting, exercise, individual sports, team sports, and other strength training. Given the pervasive use of legal PES and current proposed legislation regarding the sale of legal PES to minors, research on long-
Table 1. Descriptive and health characteristics of 11,996 young adult participants in the National Longitudinal Study of adolescent health.

|                                | Legal PES Use | No legal PES Use |
|--------------------------------|---------------|------------------|
| **N**                          | 963           | 11,033           |
| **Demographic characteristics** |               |                  |
| Age, years                     | 21.7 ± 0.1    | 21.8 ± 0.1       | 0.523 |
| Sex                            |               |                  |
| Male                           | 93.2%         | 46.8%            | <0.001|
| Female                         | 6.8%          | 53.3%            |       |
| Race/ethnicity                 |               |                  |
| White (non-Hispanic)           | 77.0%         | 67.6%            | <0.001|
| Black/African American (non-Hispanic) | 9.1%    | 16.0%            |       |
| Hispanic/Latino                | 9.9%          | 12.0%            |       |
| Asian/Pacific Islander (non-Hispanic) | 2.5%    | 3.1%             |       |
| American Indian/Native American| 0.6%          | 3.2%             |       |
| Other                          | 0.9%          | 0.8%             |       |
| Household income, US dollars (Wave I, 11–18 years old) | 52.7 ± 2.1 | 45.4 ± 1.4 | <0.001 |
| College education or more (Wave IV, 24–32 years old) | 82.8% | 73.6% | <0.001 |
| **Health behaviors** (Wave III, 18–26 years old) | | |
| Alcohol use, ≥2 days in the past month | 69.2% | 43.9% | <0.001 |
| Smoking, past 30 days          | 38.7%         | 35.5%            | 0.181 |
| Weight lifting to bulk up, past 7 days | 33.6% | 6.0% | <0.001 |
| Exercise to bulk up, past 7 days | 29.3% | 6.4% | <0.001 |
| Number of times participated in individual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or martial arts), past 7 days | 1.2 ± 0.1 | 0.6 ± 0.0 | <0.001 |
| Number of times participated in strenuous team sports (football, soccer, basketball, lacrosse, rugby, field hockey, ice hockey), past 7 days | 0.9 ± 0.1 | 0.4 ± 0.0 | <0.001 |
| Number of times participated in gymnastics, weight lifting, or strength training, past 7 days | 2.6 ± 0.1 | 0.8 ± 0.0 | <0.001 |
| Anabolic androgenic steroid use, between Wave I and III | 13.7% | 0.80% | <0.001 |
| **Health behaviors** (Wave IV, 24–32 years old) | | |
| Alcohol use, ≥2 days in the past month | 68.8% | 46.1% | <0.001 |
| Smoking, past 30 days          | 38.3%         | 37.6%            | 0.789 |
| Number of times participated in individual sports (running, wrestling, swimming, cross-country skiing, cycle racing, or martial arts), past 7 days | 1.2 ± 0.1 | 0.7 ± 0.0 | <0.001 |
| Number of times participated in strenuous team sports (football, soccer, basketball, lacrosse, rugby, field hockey, ice hockey), past 7 days | 0.5 ± 0.0 | 0.3 ± 0.0 | <0.001 |
| Number of times participated in gymnastics, weight lifting, or strength training, past 7 days | 2.0 ± 0.1 | 0.8 ± 0.0 | <0.001 |
| **Physical health factors** (Wave III, 18–26 years) | | |
| Body mass index                | 26.2 ± 0.2    | 26.5 ± 0.1       | 0.176 |
| Diabetes, self-report          | 1.1%          | 0.9%             | 0.774 |
| Hypertension, self-report      | 6.1%          | 5.5%             | 0.626 |
| Hyperlipidemia, self-report    | 4.0%          | 4.3%             | 0.746 |
| **Physical health factors** (Wave IV, 24–32 years old) | | |
| Body mass index                | 28.7 ± 0.2    | 29.1 ± 0.2       | 0.230 |
| Diabetes, self-report          | 2.1%          | 2.7%             | 0.323 |
| Diabetes, self-report, hemoglobin A1c, medications | 5.9% | 6.6% | 0.474 |
| Hemoglobin A1c                 | 5.6 ± 0.0     | 5.6 ± 0.0        | 0.802 |
| Hypertension, self-report      | 14.9%         | 10.5%            | 0.007 |
| Hypertension, self-report, blood pressure, medications | 58.0% | 51.3% | 0.012 |
| Systolic blood pressure        | 128.8 ± 0.6   | 124.7 ± 0.2      | <0.001 |

(Continued)
term health effects of legal PES are warranted, especially given the paucity of studies and the lack of regulation by the Food and Drug Administration.

Our findings are consistent with earlier empirical research suggesting that legal PES use has few harmful effects on key risk factors for CVD. Previous research indicates that short- and long-term engagement of common PES, such as creatine and pre-workout supplements, do not pose a risk with respect to blood lipid profiles or hemodynamic properties [21, 51]. Our study extended these prior results, which were limited to a small sample of athletes, to investigate health outcomes of legal PES users over a longer time period in a much larger, general population sample without medical oversight. Additionally, although previous research has found an association between creatine use and weight gain [23], we did not find such a link, even in unadjusted analyses. This lack of association may provide a primary explanation for why we did not find an association between legal PES use and CVD risk, as weight and BMI are primary risk factors for CVD [24]. This may be in part due to our longer seven-year follow-up period, as well as the dichotomous operationalization of legal PES use and the overall broader conceptualization of legal PES that was not restricted to creatine only.

Table 1. (Continued)

| Health outcomes                     | Legal PES Use | No legal PES Use |
|--------------------------------------|---------------|------------------|
| Diastolic blood pressure             | 80.2 ± 0.5    | 79.3 ± 0.2       | 0.058 |
| Hyperlipidemia, self-report          | 8.6%          | 8.2%             | 0.778 |
| Hyperlipidemia, self-report, labs, medications | 14.8%         | 16.7%            | 0.256 |
| Total cholesterol decile             | 5.5 ± 0.1     | 5.6 ± 0.1        | 0.836 |
| LDL cholesterol decile               | 5.6 ± 0.2     | 5.6 ± 0.1        | 0.986 |
| HDL cholesterol decile               | 4.9 ± 0.1     | 5.5 ± 0.1        | <0.001 |
| Triglyceride decile                  | 5.9 ± 0.1     | 5.6 ± 0.1        | 0.015 |

PES = performance-enhancing substance (such as creatine monohydrate or andro)

*All means and percentages are calculated with weighted data to reflect the representative proportion in the target US population.

https://doi.org/10.1371/journal.pone.0244018.t001

Table 2. Associations between legal performance-enhancing substance use and continuous cardiovascular disease risk factors among young adults at seven-year follow-up.

| Seven-year follow-up outcomes (ages 24–32 years) | Unadjusted | Adjusted, demographics*a | Fully adjustedb |
|--------------------------------------------------|------------|--------------------------|-----------------|
| Cardiovascular disease risk factors              | B (95% CI) | p                        | B (95% CI)      | p |
| Hemoglobin A1c                                    | -0.01 (-0.08–0.06) | 0.802                   | -0.04 (-0.11–0.02) | 0.194 |
| Systolic blood pressure                           | 4.15 (2.96–5.34)   | <0.001                   | -0.49 (-1.69–0.72) | 0.427 |
| Diastolic blood pressure                          | 0.90 (-0.03–1.84)   | 0.058                    | -1.38 (-2.36–0.41) | 0.006 |
| Total cholesterol decile                          | 0.03 (-0.32–0.26)   | 0.836                    | -0.15 (-0.45–0.14) | 0.306 |
| LDL cholesterol decile                            | 0.00 (-0.32–0.32)   | 0.986                    | -0.11 (-0.43–0.21) | 0.503 |
| HDL cholesterol decile                            | -0.54 (-0.81–0.28)  | <0.001                   | -0.15 (-0.43–0.14) | 0.312 |
| Triglyceride decile                               | 0.32 (0.06–0.58)    | 0.015                    | -0.02 (-0.37–0.24) | 0.665 |
| Body mass index                                   | -0.33 (-0.88–0.21)  | 0.230                    | -0.01 (-0.36–0.34) | 0.958 |
| Body mass index change                            | 0.00 (-0.36–0.35)   | 0.990                    | 0.01 (-0.37–0.38) | 0.971 |

*aAdjusted for age, sex, race/ethnicity, and BMI, hypertension, hyperlipidemia, or diabetes at Wave III.

*bAdjusted for age, sex, race/ethnicity, household income, highest education, smoking, alcohol, anabolic-androgenic steroid use, weightlifting, exercise, strength training, individual sports, team sports, BMI, and hypertension, hyperlipidemia, or diabetes at Wave III. * indicates adjusted for measures at both Wave III and Wave IV.

https://doi.org/10.1371/journal.pone.0244018.t002
Additionally, our study adjusted for a large number of theoretically salient sociodemographic, behavioral, and health-related covariates, which were not accounted for in previous research. For example, Or and colleagues only controlled for age and gender [11], whereas in our study, the significant prospective associations between legal PES use and CVD risk that were found in unadjusted models were no longer significant when adjusting for Wave III CVD risk, broader sociodemographics, and other relevant behavioral variables. Thus, the association between legal PES and medical outcomes may be an indirect one, accounted for by the propensity of legal PES users to engage in other risky behaviors and to develop substance use and mental disorders. Further, Or and colleagues’ comparison group was composed of vitamin users, a subset of the population that have been shown to exhibit better health outcomes compared to the general population [52, 53]. Thus, the pro-health behaviors in that population may have contributed to the significant differences detected in that study moreso than the deleterious effects of PES. Finally, it is possible that the association between PES use and severe medical events may not be specifically related to CVD risk factors and may instead be the result of deleterious impacts on other organ systems (e.g., renal dysfunction [23]).

### Strengths and limitations

There are several limitations regarding the assessment of legal PES use. First, legal PES use was assessed as one broad category. While some examples were provided (such as creatine or andro), the Add Health survey did not list all examples of legal PES, which could also include β-alanine, L-carnitine, energy drinks, or others. Specific types of legal PES, such as those containing surreptitious AAS, selective androgen receptor modulators (SARMs), or other anabolic substances that are technically legal but sold primarily over the internet, could have associations with CVD risk; however, we were unable to separately analyze distinct types of legal PES. Second, the legal PES measure (yes/no) did not assess frequency, amount, or duration of use. It is possible that detecting significant associations with the health-related outcomes assessed here would require more precise dose- and duration-specific data. This is consistent with the notion that lasting physiological effects of substance use, including AAS [42], are exacerbated with longer duration and higher amounts of use. Third, the Add Health survey did not collect legal PES data at Wave IV so information on the rate maintaining legal PES use over a seven-year period is not available. Further, the concurrent use of multiple PES (e.g., creatine, pre-workout, prohormones as part of a PES regimen) could also be more likely to be significantly associated with greater CVD risk. In the current study, short-term, infrequent, and/or minimal use was indistinguishable from long-term, frequent, and high levels of use, and this

![Table 3. Associations between legal performance-enhancing substance use and binary clinical cardiovascular disease risk factor outcomes among young adults at seven-year follow-up.](https://doi.org/10.1371/journal.pone.0244018.t003)

| Seven-year follow-up outcomes (ages 24–32 years) | Unadjusted | Adjusted, demographics<sup>a</sup> | Fully adjusted<sup>b</sup> |
|--------------------------------------------------|------------|----------------------------------|--------------------------|
| Cardiovascular disease risk factors              | Odds ratio (95% CI) | p | Odds ratio (95% CI)<sup>a</sup> | p | Odds ratio (95% CI)<sup>b</sup> | p |
| Diabetes                                         | 0.88 (0.62–1.26) | 0.496 | 0.94 (0.66–1.34) | 0.713 | 1.37 (0.93–2.02) | 0.107 |
| Hypertension                                     | 1.31 (1.06–1.62) | 0.012 | 0.78 (0.62–0.97) | 0.027 | 0.86 (0.68–1.10) | 0.232 |
| Hyperlipidemia                                   | 0.86 (0.67–1.12) | 0.276 | 0.83 (0.62–1.10) | 0.198 | 0.94 (0.70–1.26) | 0.676 |
| Obesity                                          | 0.93 (0.78–1.11) | 0.414 | 1.08 (0.87–1.34) | 0.505 | 1.25 (0.98–1.59) | 0.069 |

<sup>a</sup>Adjusted for age, sex, race/ethnicity, and BMI, hypertension, hyperlipidemia, or diabetes at Wave III.

<sup>b</sup>Adjusted for age, sex, race/ethnicity, household income, highest education, smoking, alcohol, anabolic-androgenic steroid use, weightlifting, exercise, strength training, individual sports, team sports, BMI, and hypertension, hyperlipidemia, or diabetes at Wave III. " indicates adjusted for measures at both Wave III and Wave IV.
In addition to the limitations regarding the assessment of PES use described above, another potential limitation of the study includes the use of self-reported measures, which could lead to reporting bias. We attempted to mitigate this by incorporating self-report of a physician diagnosis and objective measures into the Wave IV outcomes (the objective measures were not recorded at Wave III). Further, although the follow-up period in this study was seven years, it is possible that the medical and physiological effects of PES use, particularly if prolonged, emerge after a longer period of time or in age groups older than the young adult range reflected in the current sample. Although we adjusted for a large number of potential confounders, it is possible there were unmeasured confounders we were not able to adjust for. For instance, while we adjusted for frequency of sports participation, Add Health did not collect data on physical activity intensity or duration. Despite these limitations, however, there were numerous strengths to this study. First, we investigated a large, nationally representative sample and addressed an under-researched topic with important policy implications. Additionally, we extended the existing literature in this area by accounting for numerous theoretically-important covariates related to CVD risk which have not typically been included in previous studies on this topic. Further, the long-term, prospective nature of the study design contributes to the literature that has often focused on only short-term or immediate effects.

Conclusions

While our study found no significant prospective associations between legal PES use and CVD risk factors, there remains a need for ongoing research into the long-term health outcomes of legal PES use. As noted by Pope et al. (2014), it is unlikely that randomized controlled trials will be conducted to test the outcomes of these substances [38]. This is in part due to the lack of funding, the unregulated nature of PES, and the potential risks associated with administering supraphysiologic doses of PES in clinical trials. Therefore, despite certain limitations inherent to their design, longitudinal cohort studies will represent invaluable sources of future data on the outcomes associated with legal PES use. Further, it will be important to account for the many confounding factors that may either exacerbate or protect against any potential adverse health outcomes. This may include exercise duration and intensity, dietary intake and eating patterns, health care utilization, income, stress, medical and mental health history, other substance use or misuse, and family medical and mental health history. Future research should investigate both the benefits and risks associated with legal PES use across age groups, as well as explore outcomes relevant to other organ systems of the body, such as the renal and liver systems.

In sum, there is growing evidence that legal PES use is common among adolescents and young adults, particularly among boys and men [1, 2], and these substances are unregulated and easily accessible in the US [3]. Despite the null findings in this study, prior research indicated that adverse health [11] and social [10, 47] outcomes are associated with legal PES use and our unadjusted models indicated that legal PES use was associated with certain CVD risk factors after seven years; however, it was apparent that other sociodemographic and behavioral variables better explained this association, as the associations were no longer significant in the fully adjusted models. Amid the lack of federal policy and oversight in the US, state policies have been introduced that aim to regulate the sale of these substances to minors, as well as provide detailed labeling that outlines the lack of oversight and research on outcomes associated with their use [54, 55]. Given these policies, it is imperative that research be funded and conducted to provide data on the safety and health effects, both risks and benefits, of legal PES use.
in order to inform public policy. Lastly, implementation and evaluation science will be needed to assess the effectiveness of any policies passed into law.

**Acknowledgments**

The authors thank Samuel Benabou for editorial assistance.

**Author Contributions**

**Conceptualization:** Jason M. Nagata, Kyle T. Ganson, Stuart B. Murray.

**Formal analysis:** Jason M. Nagata.

**Investigation:** Jason M. Nagata.

**Methodology:** Jason M. Nagata, Kyle T. Ganson, Mitchell L. Cunningham, Deborah Mitchison.

**Writing – original draft:** Jason M. Nagata, Kyle T. Ganson, Mitchell L. Cunningham, Stuart B. Murray.

**Writing – review & editing:** Jason M. Nagata, Kyle T. Ganson, Mitchell L. Cunningham, Deborah Mitchison, Jason M. Lavender, Aaron J. Blashill, Holly C. Gooding, Stuart B. Murray.

**References**

1. Eisenberg ME, Wall M, Neumark-Sztainer D. Muscle-enhancing behaviors among adolescent girls and boys. *Pediatrics*. 2012; 130: 1019–1026. [https://doi.org/10.1542/peds.2012-0095](https://doi.org/10.1542/peds.2012-0095) PMID: 23166333

2. Nagata JM, Ganson KT, Griffiths S, Mitchison D, Garber AK, Vittinghoff E, et al. Prevalence and correlates of muscle-enhancing behaviors among adolescents and young adults in the United States. *Int J Adolesc Med Heal*. 2020. [https://doi.org/10.1515/ijamh-2020-0001](https://doi.org/10.1515/ijamh-2020-0001) PMID: 32549173

3. Ganson KT, Murray SB, Nagata JM. A call for public policy and research to reduce use of appearance and performance enhancing drugs and substances among adolescents. *Lancet Child Adolesc Heal*. 2020; 4: 13–14. [https://doi.org/10.1016/S2352-4642(19)30345-1](https://doi.org/10.1016/S2352-4642(19)30345-1)

4. Ackard DM, Neumark-Sztainer D, Story M, Perry C. Overeating among adolescents: prevalence and associations with weight-related characteristics and psychological health. *Pediatrics*. 2003; 111: 67–74. [https://doi.org/10.1542/peds.111.1.67](https://doi.org/10.1542/peds.111.1.67) PMID: 12509556

5. Pope HG, Kouli EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial. *Arch Gen Psychiatry*. 2000; 57: 133–140. [https://doi.org/10.1001/archpsyc.57.2.133](https://doi.org/10.1001/archpsyc.57.2.133) PMID: 10665615

6. Lundholm L, Käll K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. *Drug Alcohol Depend*. 2010; 111: 222–226. [https://doi.org/10.1016/j.drugalcdep.2010.04.020](https://doi.org/10.1016/j.drugalcdep.2010.04.020) PMID: 20627426

7. Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. In *Handbook of Experimental Pharmacology*. Handb Exp Pharmacol; 2010. pp. 411–457. [https://doi.org/10.1007/978-3-540-79088-4_18](https://doi.org/10.1007/978-3-540-79088-4_18) PMID: 20020375

8. Nikolopoulou DD, Spiliopoulou C, Theocharis SE. Doping and musculoskeletal system: Short-term and long-lasting effects of doping agents. *Fundam Clin Pharmacol*, 2011; pp. 553–563. [https://doi.org/10.1111/j.1472-8206.2010.00881.x](https://doi.org/10.1111/j.1472-8206.2010.00881.x) PMID: 21039821

9. Brenu E W., McNaughton L M. Marshall-Gradišnik S. Is there a Potential Immune Dysfunction with Anabolic Androgenic Steroid Use?: A Review. *Mini-Reviews Med Chem*. 2011; 11: 438–445. [https://doi.org/10.2174/138955711795445907](https://doi.org/10.2174/138955711795445907) PMID: 21443507

10. Nagata JM, Ganson KT, Gorrell S, Mitchison D, Murray SB. Association Between Legal Performance-Enhancing Substances and Use of Anabolic-Androgenic Steroids in Young Adults. *JAMA Pediatr*. 2020 [cited 23 May 2020]. [https://doi.org/10.1001/jamapediatrics.2020.0863](https://doi.org/10.1001/jamapediatrics.2020.0863) PMID: 32421175

11. Or F, Kim Y, Simms J, Austin SB. Taking Stock of Dietary Supplements’ Harmful Effects on Children, Adolescents, and Young Adults. *J Adolesc Heal Off Publ Soc Adolesc Med*. 2019. [https://doi.org/10.1016/j.jadohealth.2019.03.005](https://doi.org/10.1016/j.jadohealth.2019.03.005) PMID: 31176525
12. Gooding HC, Milliren C, Shay CM, Richmond TK, Field AE, Gillman MW. Achieving cardiovascular health in young adulthood—which adolescent factors matter? J Adolesc Health. 2016; 58: 119–121. https://doi.org/10.1016/j.jadohealth.2015.09.011 PMID: 26707234

13. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. 2020; 141: e139–e596. https://doi.org/10.1161/CIR.0000000000000757 PMID: 31992061

14. La Gerche A, Brosnan MJ. Cardiovascular Effects of Performance-Enhancing Drugs. Circulation. 2017; 135: 89–99. https://doi.org/10.1161/CIRCULATIONAHA.116.022535 PMID: 28028062

15. Murray SB, Nagata JM, Griffiths S, Calzo JP, Brown TA, Mitchison D, et al. The enigma of male eating disorders: A critical review and synthesis. Clinical Psychology Review. Elsevier Inc.; 2017. pp. 1–11. https://doi.org/10.1016/j.cpr.2017.08.001 PMID: 28800416

16. Nagata JM, Brown TA, Lavender JM, Murray SB. Emerging trends in eating disorders among adolescent boys: muscles, macronutrients, and biohacking. Lancet Child Adolesc Heal. 2019; 3: 444–445. https://doi.org/10.1016/S2352-4642(19)30147-6

17. Nagata JM, Peebles R, Hill KB, Gorrell S, Carlson JL. Associations between ergogenic supplement use and eating behaviors among university students. Eat Disord. 2020 [cited 28 Oct 2020]. https://doi.org/10.1080/10640266.2020.1712637 PMID: 32129729

18. Nagata JM, Garber AK, Tabler J, Murray SB, Vittinghoff E, Bibbins-Domingo K. Disordered eating behaviors and cardiometabolic risk among young adults with overweight or obesity. Int J Eat Disord. 2018; 51: 931–941. https://doi.org/10.1002/eat.22927 PMID: 30030944

19. Sachs K V, Harnke B, Mehler PS, Krantz MJ. Cardiovascular complications of anorexia nervosa: A systematic review. Int J Eat Disord. 2016; 49: 238–248. https://doi.org/10.1002/eat.22481 PMID: 26710932

20. LaBotz M, Griesemer BA, MEDICINE CONS, FITNESS. Use of Performance-Enhancing Substances. Pediatrics. 2016; 138: https://doi.org/10.1542/peds.2016-1300 PMID: 27354458

21. Kreider RB, Melton C, Rasmussen CJ, Greenwood M, Lancaster S, Cantler EC, et al. Long-term creatine supplementation does not significantly affect clinical markers of health in athletes. Molecular and Cellular Biochemistry. 2003. pp. 95–104. https://doi.org/10.1023/A:1022469320296

22. Pinto CL, Botelho PB, Pimentel GD, Campos-Ferraz PL, Mota JF. Creatine supplementation and glycemic control: a systematic review. Amino Acids. Springer-Verlag Wien; 2016. pp. 2103–2129. https://doi.org/10.1007/s00726-016-2277-1 PMID: 27306768

23. Kreider RB, Kalman DS, Antonio J, Ziegenspeck TN, Wildman R, Collins R, et al. International Society of Sports Nutrition position stand: Safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. BioMed Central Ltd.; 2017. https://doi.org/10.1186/s12970-017-0173-z PMID: 28615996

24. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007; 357: 2371–2379. https://doi.org/10.1056/NEJMsa073168 PMID: 18057339

25. Torres-Acosta N, O’Keefe JH, O’Keefe CL, Lavie CJ. Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week. Journal of the American College of Cardiology. Elsevier USA; 2020. pp. 858–866. https://doi.org/10.1016/j.jacc.2020.05.081 PMID: 32792083

26. Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. Springer International Publishing; 2017. pp. 199–215. https://doi.org/10.1007/s40263-017-0410-7 PMID: 28236285

27. Grasser EK, Miles-Chan JL, Charrière N, Loonam CR, Dulloo AG, Montani JP. Energy drinks and their impact on the cardiovascular system: Potential mechanisms. Advances in Nutrition. American Society for Nutrition; 2016. pp. 950–960. https://doi.org/10.3945/an.116.012526 PMID: 27633110

28. Pickering C, Grigic J. Caffeine and Exercise: What Next? Sports Medicine. Springer International Publishing; 2019. pp. 1007–1030. https://doi.org/10.1007/s40279-019-01101-0 PMID: 30977054

29. Green GA, Catlin DH, Starcic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med. 2001; 11: 254–259. https://doi.org/10.1097/00042752-200110000-00008 PMID: 11753063

30. Van Wagener RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA—J Am Med Assoc. 2017; 318: 2004–2010. https://doi.org/10.1001/jama.2017.17069 PMID: 29183075

31. Cohen PA. American Roulette—Contaminated dietary supplements. N Engl J Med. 2009; 361: 1523–1525. https://doi.org/10.1056/NEJMtp0904768 PMID: 19812394
32. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W. Analysis of Non-Hormonal Nutritional Supplements for Anabolic-Androgenic Steroids—Results of an International Study. Int J Sports Med. 2004; 25: 124–129. https://doi.org/10.1055/s-2004-819955 PMID: 14986195

33. Martínez-Sanz JM, Sospedra I, Ortiz CM, Baladí E, Gil-Izquierdo A, Ortiz-Moncada R. Intended or unintended doping? A review of the presence of doping substances in dietary supplements used in sports. Nutrients. MDPI AG; 2017. https://doi.org/10.3390/nu9101093 PMID: 28976928

34. Mathews NM. Prohibited Contaminants in Dietary Supplements. Sports Health. 2018; 10: 19–30. https://doi.org/10.1177/1941738117727736 PMID: 28850291

35. Geyer H, Parr MK, Koehler K, Mareck U, Schänzer W, Thevis M. Nutritional supplements cross-contaminated and faked with doping substances. Journal of Mass Spectrometry. J Mass Spectrom; 2008. pp. 892–902. https://doi.org/10.1002/jms.1452 PMID: 18563865

36. Van Poucke C, Detavernier C, Van Cauwenberghe R, Van Peteghem C. Determination of anabolic steroids in dietary supplements by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2007; 586: 35–42. https://doi.org/10.1016/j.aca.2006.09.050 PMID: 17386694

37. Perry JC, Schuetz TM, Memon MD, Faiz S, Cancarevic I. Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus. 2020; 12. https://doi.org/10.7759/cureus.9333 PMID: 32850208

38. Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014; 35: 341–375. https://doi.org/10.1210/er.2013-1058 PMID: 24423981

39. Liu J Di, Wu YQ, Cui Y. Anabolic-androgenic steroids and cardiovascular risk. Chinese Medical Journal. Lippincott Williams and Wilkins; 2019. pp. 2229–2236. https://doi.org/10.1097/CM9.0000000000000407 PMID: 31478927

40. Angel P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Medicine. Sports Med; 2012. pp. 119–134. https://doi.org/10.2165/11598060-000000000-00000 PMID: 22229259

41. Pereira Dos Santos MA, Coutinho De Oliveira CV, Silva AS. Adverse cardiovascular effects from the use of anabolic-androgenic steroids as ergogenic resources. Subst Use Misuse. 2014; 49: 1132–1137. https://doi.org/10.3109/10826084.2014.903751 PMID: 24832723

42. Kanayama G, Hudson JI, Pope HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: A looming public health concern? Drug and Alcohol Depend. Drug Alcohol Depend; 2008. pp. 1–12. https://doi.org/10.1016/j.drugalcdep.2008.05.004 PMID: 18599224

43. Harris KM, Halpern CT, Whitsel E, Hussey J, Tabor J, Entzel P, et al. The National Longitudinal Study of Adolescent to Adult Health: Research Design. 2017. Available: https://www.cpc.unc.edu/projects/addhealth/design/researchdesign_3618_regular.pdf

44. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 Suppl 1: S1. https://doi.org/10.2337/dc14-1041 PMID: 23959568

45. Wheelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ASH/ASCPC/SCM/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines. Hypertension. Lippincott Williams and Wilkins; 2018. pp. E13–E115. https://doi.org/10.1161/HYP.00000000000065 PMID: 29133356

46. Shay CM, Ning H, Allen NB, Carnethon MR, Chiuve SE, Greenlund KJ, et al. Status of cardiovascular health in US adults: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003–2008. Circulation. 2012; 125: 45–56. https://doi.org/10.1161/CIRCULATIONAHA.111.035733 PMID: 22095826

47. Ganson KT, Mitchison D, Murray SB, Nagata JM. Legal performance-enhancing substances and substance use problems among young adults. Pediatrics. 2020; 146: e20200409. https://doi.org/10.1542/peds.2020-0409 PMID: 32868471

48. Hamad R, Penko J, Kazi DS, Coxson P, Guzman D, Wei PC, et al. Association of low socioeconomic status with premature coronary heart disease in US adults. JAMA Cardiol. 2020 [cited 26 Jul 2020]. https://doi.org/10.1001/jamacardio.2020.1458 PMID: 32459344

49. Nagata JM, Palar K, Gooding HC, Garber AK, Bibbins-Domingo K, Weiser SD. Food Insecurity and Chronic Disease in US Young Adults: Findings from the National Longitudinal Study of Adolescents to Adult Health. J Gen Intern Med. 2019; 34: 2756–2762. https://doi.org/10.1007/s11606-019-05317-8 PMID: 31576599

50. Chen P, Harris KM. Guidelines for Analyzing Add Health Data. 2020. Available: https://addhealth.cpc.unc.edu/wp-content/uploads/docs/user_guides/GuidelinesforAnalysisofAddHealthData_202004.pdf
51. Harty PS, Zabriskie HA, Erickson JL, Molling PE, Kerksick CM, Jagim AR. Multi-ingredient pre-workout supplements, safety implications, and performance outcomes: A brief review. Journal of the International Society of Sports Nutrition. BioMed Central Ltd.; 2018. https://doi.org/10.1186/s12970-018-0247-6 PMID: 30089501

52. Qato DM, Caleb Alexander G, Guadamuz JS, Lindau ST. Prevalence of dietary supplement use in us children and adolescents, 2003–2014. JAMA Pediatrics. American Medical Association; 2018. pp. 780–782. https://doi.org/10.1001/jamapediatrics.2018.1008 PMID: 29913013

53. Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, et al. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: A cross-sectional study. Nutr J. 2007;6. https://doi.org/10.1186/1475-2891-6-6 PMID: 17386092

54. State of New York. NY State Senate Bill S8089 Relates to establishing restrictions on the sale of over-the-counter diet pills and dietary supplements for weight loss or muscle building. 2020 [cited 17 Jun 2020]. Available: https://www.nysenate.gov/legislation/bills/2019/s8089

55. State of Massachusetts. MA State Bill H.1942 An act protecting children from harmful diet pills and muscle-building supplements. 2020 [cited 17 Jun 2020]. Available: https://malegislature.gov/Bills/191/HD2883